NICE recommends new hepatitis C drug

25 January 2017
2019_biotech_test_vial_discovery_big

In final guidance issued today, the National Institute of Clinical Excellence (NICE) has approved Epclusa (sofosbuvir 400mg/velpatasvir 100mg), for the treatment of adults with chronic hepatitis C genotypes 1-6 infection, thus confirming a draft guidance from the medicines cost-effectiveness watchdog for England and Wales issued last September.

US biotech major Gilead Sciences (Nasdaq: GLD), the drug’s maker, welcomes the NICE’s recommendation, noting that Epclusa is the only all-oral single tablet regimen licensed for all genotypes (1-6) of chronic hepatitis C virus. It is also the first single tablet regimen licensed in the UK for the treatment of patients with hepatitis C genotypes 2 and 3 (without decompensated cirrhosis), without the need for ribavirin.

It is estimated that around 214,000 people in the UK have chronic hepatitis C, but many remain undiagnosed. Without treatment, hepatitis C can cause serious liver damage and potentially life-threatening complications, such as liver cancer, and may also lead to significant implications on the NHS.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology